Shareholders Approve 5M Share Increase for Equity Incentive Plan
NEO sits 96% above its 52-week low of $4.72 on light trading volume (0.4× avg).
Summary
NeoGenomics stockholders approved an amendment to increase the shares authorized for its equity incentive plan by 5 million, representing potential future dilution of approximately 3.84%.
Key Events · Corporate Governance and Compliance · NEO
-
Equity Incentive Plan Expanded
Stockholders approved an amendment to the 2023 Equity Incentive Plan, authorizing an additional 5,000,000 shares for future issuance.
-
Potential Dilution
This authorization represents a potential dilution of approximately 3.84% of the company's outstanding shares if all new shares are issued.
-
Annual Meeting Approvals
Shareholders also re-elected all nine directors, approved executive compensation on an advisory basis, and ratified the independent auditor.
Analysis · NEO · Industrial Applications And Services
NeoGenomics stockholders approved an amendment to increase the shares authorized for its 2023 Equity Incentive Plan by 5,000,000. This authorization provides the company with a larger pool of shares for future employee and executive compensation, which is crucial for talent retention. However, it also introduces potential future dilution for existing shareholders, estimated at approximately 3.84% of current outstanding shares. This 8-K finalizes the proposal that was initially presented in the definitive proxy statement filed on April 6, 2026.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NEO was trading at $9.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.72 to $13.74. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.